Epzicom Conference Citations

Medical Advocates
Abacavir/Lamivudine (Epzicom)

Conference Citations

19th CROI
6th IAS Conference
18th CROI
16th CROI
Ninth Int Congress on Drug Therapy in HIV Infection
4th IAS Conference
15th CROI
8th Int Congress on Drug Therapy in HIV Infection
XVI International AIDS Conference
13th CROI
3rd IAS Conference
XV International AIDS Conference
XIV International AIDS Conference

Epzicom Main Page Main New/Newsworthy Home Page

Last Updated: March 10, 2012

Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader\

19th Conference on Retroviruses and
Opportunistic Infections

POSTER
Changes in Subcutaneous Fat Mitochondrial DNA and Function in ART-naļve Subjects Randomized to Abacavir/Lamivudine
or Tenofovir/Emtricatibine with Atazanavir/ritonavir or Efavirenz: ACTG A5224s, a Sub-study of A5202
G McComsey, E Daar, MA O’Riordanm, et al
PDF Poster Abstract
POSTER
Changes in Inflammation and Endothelial Activation Markers in ARV-naļve Subjects Randomized to Abacavir/Lamivudine
or Tenofovir/Emtricitabine along with Efavirenz or Atazanavir/ritonavir: AIDS Clinical Trials Group A5224s, a Sub-study of
ACTG A5202
G McComsey, D Kitch, E Daar, et al
PDF Poster Abstract

6th IAS Conference on HIV Pathogenesis, Treatment
and Prevention

POSTER
Long-term efficacy and safety of abacavir/lamivudine (ABC/3TC) and raltegravir (RAL) in antiretroviral naive HIV-1 infected subjects
B. Young, T. Vanig, E. DeJesus, et al
Poster Abstract
POSTER
Changes in inflammatory biomarker levels, including lipoprotein-associated phospholipase A2 (Lp-PLA2) levels
and correlation with framingham (FRAM) risk scores in antiretroviral (ART)-naive patients through 144 weeks of
abacavir/lamivudine (ABC/3TC)
B. Young, K. Squires, L. Ross, et al
Poster Abstract
Renal toxicity for switching from tenofovir/emtricitabine (TDF/FTC) to abacavir/lamivudine(ABC/3TC):
an association to be clarified
L. Manzini, V. Borghi, S. Rusconi, et al
Abstract

18th Conference on Retroviruses and
Opportunistic Infections

A WEEK-IN-REVIEW FEATURED REPORT
Central Fat Accumulation in ART-naļve Subjects Randomized to ABC/3TC or TDF/FTC
with ATV/r or EFV: ACTG A5224s, a Substudy of ACTG A5202
G McComsey, D Kitch, P Sax. et al 18 CROI

16th Conference on Retroviruses and
Opportunistic Infections

POSTER
Similar Reductions in Markers of Inflammation and Endothelial Activation after Initiation of Abacavir/Lamivudine or
Tenofovir/Emtricitabine: The HEAT Study
G McComsey, K Smith, P Patel, et al
PDF Poster Abstract
POSTER
Pharmacokinetic Study of Once- vs Twice-daily Abacavir and Lamivudine as Part of Combination ART in Children
with HIV-1 Infection aged 3 to 36 months: Pediatric European Network for Treatment of AIDS 15 and ANRS 133
E Jacqz-Aigrain, L Farrelly, A Compagnucci, et al
PDF Poster Abstract

Ninth International Congress on Drug Therapy in HIV Infection

Comparing the efficacy of Truvada and Kivexa combination therapy in HAART-naive individuals with different viral loads
Daniels RH, Gazzard BG, Holmes P, et al
Abstract
The TOKEN study: safety and efficacy of Truvada or Kivexa in combination with efavirenz in treatment-naļve
predominantly black African HIV patients
Das S, Arumainayagam J, Kumari B, et al
Abstract
Abacavir/lamivudine has shown similar efficacy to other nucleoside conventional combinations in previously
HIV-infected patients: results at 48 weeks
Echeverrķa P, De la Torre J, Pasquau J, et al
Abstract

15th Conference on Retroviruses and
Opportunistic Infections

Efficacy and Safety of Abacavir/Lamivudine Compared to Tenofovir/Emtricitabine in
Combination with Once-daily Lopinavir/Ritonavir through 48 Weeks in the HEAT Study
K Smith, D Fine, P Patel, et al
Abstract

4th IAS Conference on HIV Pathogenesis, Treatment
and Prevention

Once-daily abacavir/lamivudine (ABC/3TC) and boosted atazanavir (ATV/RTV) in antiretroviral-naive
HIV-1 infected subjects: 48-week results from COL102060 (SHARE)
Elion R, DeJesus E, Sension M, et al
Abstract

8th Int Congress on Drug Therapy in HIV Infection

Switching from twice daily (BID) abacavir (ABC) and lamivudine (3TC) to a fixed dose
combination (FDC) of ABC/3TC taken once daily (QD) improves patient adherence and
satisfaction with therapy
D Maitland, A Jackson, J Osorio, et al
Abstract
ABC/3TC in combination with a boosted PI in clinical practice
A Carganico, S Dupke, B Hintsche, et al
Abstract
Once-daily (QD) abacavir (ABC)/lamivudine (3TC) and ritonavir-boosted atazanavir (ATV/r)
in antiretroviral naļve HIV-1infected subjects: 24-week analysis from COL102060 (SHARE)
R Elion, E DeJesus, M Sension, et al
Abstract

XVI International AIDS Conference

Switching from twice daily (BID) abacavir (ABC) and lamivudine (3TC) to a fixed dose
combination (FDC) of ABC/3TC taken once daily (QD) improves patient adherence and
satisfaction with therapy
Maitland D., Jackson A., Osorio J
Abstract

13th Conference on Retroviruses and
Opportunistic Infections

POSTER
A Randomized Trial of Early vs Delayed Fixed-dose Combination Zidovudine/Lamivudine/Abacavir
in Patients Co-infected with HIV and Tuberculosis: Early Findings of the Tuberculosis and HIV
Immune Reconstitution Syndrome Trial
H Shao, J Crump, H Ramadhani, et al
PDF Poster Abstract

3rd IAS Conference

POSTER
Safety of Abacavir (ABC)+Lamivudine (3TC)-based HAART in ART-Naļve HIV-Infected Subjects
With and Without Hepatitis B (HBV) and/or Hepatitis C (HCV) Co-Infection.
H Zhao, et al
PDF Poster

Efficacy and safety of a once daily fixed-dose combination of abacavir/lamivudine (ABC/3TC) [FDC ]
versus ABC twice daily and 3TC once daily as separate entities [SE] in ART-experienced HIV-1
infected subjects (CAL30001): 48 week data.
Clumeck N., LaMarca A., Fu K., et al
Abstract

Efficacy and Safety of Once-Daily Abacavir/Lamivudine Fixed-Dose Combination (ABC/3TC) +
Efavirenz (EFV): ESS30009 Planned 48 Week Analysis.
Gallant J., Rodriguez A., Weinberg W. et al
Abstract

Reported Incidence and Severity of Suspected Abacavir Hypersensitivity Reactions (HSR)
through at least 6 Weeks in a Large, Controlled Clinical Trial Using a Once-Daily (OAD)
abacavir 600mg/lamivudine 300mg tablet (ABC/3TC FDC) Dual Nucleoside Backbone with
a Boosted Protease Inhibitor: The KLEAN Study
Becker S., Yeni P., Sutherland-Phillips D, et al
Abstract

Patient satisfaction with abacavir (ABC)-lamivudine (3TC) fixed dose combination (FDC) tablet
once daily (QD) compared with ABC and 3TC twice daily (BID) in HIV-1 infected patients
ESS30008)
Watson M., Hill-Zabala C., Sosa N., et al
Abstract

XV International AIDS Conference

96 Week lipids and anthropometrics for subjects receiving initial therapy with
abacavir+lamivudine (ABC+3TC) combined with efavirenz (NNRTI), amprenavir/ritonavir (PI)
or stavudine (NRTI): ESS40001(CLASS)
K Sathasivam, SK Griffith, JA Bartlett, et al
Abstract
Initial therapy with Abacavir+ Lamivudine (ABC+3TC) combined with Efavirenz (NNRTI),
Amprenavir/Ritonavir (PI) or Stavudine (NRTI): ESS40001(CLASS)
JA Bartlett, J Johnson, G Herrer, et al
Abstract

XIV International AIDS Conference

Abacavir/Lamivudine (ABC/3TC) in combination with Efavirenz (NNRTI), Amprenavir/Ritonavir (PI)
or Stavudine (NRTI): ESS40001(CLASS) preliminary 48 week results
J Bartlett, J Johnson, G Herrera, et al
Abstract

Epzicom Main Page Main New/Newsworthy Home Page

Abacavir/ Fixed Dose Lamivudine (Epzicom)
Conference Citations